Key points from article :
LabGenius, a drug discovery company, raised £35 million in Series B funding.
The startup uses machine learning to find and design antibody therapies for cancer.
Their platform helps create molecules that target cancer cells with minimal harm to healthy cells.
Its robotic and machine learning platform can create much larger number of molecules than conventional methods.
The company focuses on both developing its own drug pipeline and partnering with pharmaceutical companies.
"These machine learning-driven discovery platforms are only any good if you can create molecules that can be progressed,” - James Field, CEO and founder of LabGenius.
LabGenius aims to maintain control of lead assets for as long as possible.
